Log in
Enquire now
Coave Therapeutics

Coave Therapeutics

Coave Therapeutics is a genetic medicines developer founded in 2014.

OverviewStructured DataIssuesContributors

All edits by  Даниил Талан 

Edits on 24 Feb, 2022
Даниил Талан profile picture
Даниил Талан
edited on 24 Feb, 2022
Edits made to:
Infobox (+1 properties)
Timeline (+4 events) (+609 characters)
Description (+169/-48 characters)
Article (+543 characters)
Table (+5 rows) (+10 cells) (+225 characters)
Topic thumbnail

Coave Therapeutics

Coave Therapeutics develops retinal gene therapy

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare ocular and CNS (Central Nervous System) diseases.

Article

We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.

...

Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

Table

Name
Role
LinkedIn

CEDRIC COUSTEIX

Finance Director

NICOLAS FERRY

M.D., Ph.D. – Chief Development Officer

PATRICIA FRANÇON

Ph.D. – Chief Operating Officer

RODOLPHE CLERVAL

M.Sc., CEFA, Chief Executive Officer

THOMAS BLAETTLER

M.D., Chief Medical Officer

Infobox
Email address
BD@COAVETX.COM
Timeline

February 24, 2022

Coave Therapeutics Closes €33 million ($39 million) Series B Financing to Develop its Gene Therapy Pipeline and Next-Generation Vectors based on its AAV-Ligand Conjugate Platform - Coave Therapeutics

February 24, 2022

Coave Therapeutics and Théa Open Innovation sign exclusive licensing, co-development and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa - Coave Therapeutics

February 24, 2022

Coave Therapeutics appoints Olivier Danos and Frederic Chereau as non-executive directors to its Board - Coave Therapeutics

February 24, 2022

2nd Gene Therapy for Ophthalmic Disorders | September 21-23 | Online

Find more companies like Coave Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.